---
title: "Intellia Therapeutics schedules conference call to discuss Q2 2026 results and business updates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294361264.md"
description: "Intellia Therapeutics has scheduled a conference call for August 6, 2026, at 8 a.m. ET to discuss its Q2 2026 financial results and provide business updates. The webcast will be accessible via a provided link, with a replay available for approximately 90 days on the company's website."
datetime: "2026-07-30T12:01:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294361264.md)
  - [en](https://longbridge.com/en/news/294361264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294361264.md)
generator: "portal-rs"
---

# Intellia Therapeutics schedules conference call to discuss Q2 2026 results and business updates

-   Intellia scheduled a conference call for Aug. 6, 2026 at 8 a.m. ET to discuss Q2 2026 results, business updates. \* Webcast access via this link (here); replay available for about 90 days on intelliatx.com (here). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300800PRIMZONEFULLFEED9799707) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md)

## Related News & Research

- [How Investors May Respond To Intellia Therapeutics Stock After Priority Review](https://longbridge.com/en/news/299050390.md)
- [Intellia says FDA accepts lonvo-z BLA for hereditary angioedema, grants priority review](https://longbridge.com/en/news/298315846.md)
- [NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects](https://longbridge.com/en/news/298966653.md)
- [Sherwin-Williams announces Q3 2026 dividend of R$ 0.28 per unit](https://longbridge.com/en/news/299050724.md)
- [Intellia awards 163,100 RSUs to 41 new employees under inducement plan](https://longbridge.com/en/news/298071320.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**